South San Francisco Newswire

Comprehensive Real-Time News Feed for South San Francisco, CA.

Results 1 - 20 of 38 for "u:pr-inside.com" in South San Francisco, CA

  1. Market Report, "Poniard Pharmaceuticals, Inc. (PARD) - Financial and...Read the original story

    10 hrs ago | PR-inside.com

    The company focused on developing picoplatin product, which is a new generation platinum based cancer therapy. Picoplatin is designed to overcome platinum resistance in the treatment of solid tumors.

    Comment?

  2. "Theravance, Inc. (THRX) - Financial and Strategic SWOT Analysis Review" PublishedRead the original story

    Saturday Jan 17 | PR-inside.com

    Theravance, Inc. is a biopharmaceutical company. The company discovers, develops and commercializes small molecule medicines.

    Comment?

  3. New Report Available: Sunesis Pharmaceuticals, Inc. - Strategy and SWOT ReportRead the original story

    Friday Jan 16 | PR-inside.com

    The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360deg view of the company.

    Comment?

  4. Rigel Pharmaceuticals, Inc. - Strategy and SWOT Report - New Study ReleasedRead the original story

    Friday Jan 16 | PR-inside.com

    Rigel Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360deg view of the company.

    Comment?

  5. Market Report, "AvidBiotics Corp. - Pharmaceuticals & Healthcare -...Read the original story

    Sunday Jan 4 | PR-inside.com

    The company develops non-antibody proteins which targets bacteria, viruses or cancer cells for human therapeutic and prophylactic uses. It develops human health care, food safety, and other products.

    Comment?

  6. New Report Available: Rigel Pharmaceuticals, Inc. (RIGL) -...Read the original story

    Saturday Jan 3 | PR-inside.com

    It discovers and develops small-molecule drugs to treat inflammatory and autoimmune diseases; and muscle disorders. The company's product pipeline comprises fostamatinib in Phase III clinical trials for the treatment of Immune Thrombocytopenic Purpura and Phase II for IgA Nephropathy ; R348 in Phase II clinical trials for the treatment of keratoconjunctivitis sicca and dry eye in patients with ocular graft-versus-host disease ; R118 in Phase I clinical trial for the treatment of intermittent claudication associated with peripheral artery disease; and two oncology products in Phase I clinical trials that are being developed with partners, BerGenBio AS and Daiichi Sankyo, respectively.

    Comment?

  7. Hyperion Therapeutics, Inc. (HPTX) - Pharmaceuticals & Healthcare -...Read the original story

    Tuesday Dec 30 | PR-inside.com

    It develops and commercializes novel drugs for the treatment of orphan diseases and hepatology disorders. Ravicti, the company's first approved product is indicated for use as a nitrogen-binding agent in adult and paediatric patients aged above two years suffering with urea cycle disorders and those who cannot be treated by dietary protein restriction and amino acid supplementation alone.

    Comment?

  8. Just Published: "Exelixis, Inc. (EXEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile"Read the original story

    Sunday Dec 28 | PR-inside.com

    Exelixis, Inc. is a biotechnology company. It focuses on the development of pharmaceutical products for treatment of cancer and other life threatening diseases.

    Comment?

  9. "NGM Biopharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile" PublishedRead the original story

    Sunday Dec 28 | PR-inside.com

    The company manufactures pharmaceutical ingredients and intermediate products that are used in animal and human health. Its products include finished dosage forms, diminazene aceturate granules and homidium chloride tablets.

    Comment?

  10. KAI Pharmaceuticals Inc. - Pharmaceuticals & Healthcare - Deals and...Read the original story

    Sunday Dec 28 | PR-inside.com

    The company discovers and develops new class of therapeutics targeting Protein Kinase C . It develops KAI-4169 used for the treatment of chronic kidney disease-mineral and bone disorder .

    Comment?

  11. Cytokinetics and Astellas Announce Expansion of Collaboration for...Read the original story

    Dec 23, 2014 | PR-inside.com

    Cytokinetics Expects to Receive Over $75 Million in Committed Capital and Reimbursements For Planned Activities Companies Plan to Initiate Phase II Clinical Trial in 2015 South San Francisco, CA, and Tokyo, December 23, 2014 - Cytokinetics, Incorporated and Astellas Pharma Inc. announced today an amendment to their collaboration agreement focused on the research, development and commercialization of skeletal muscle activators. The companies have been jointly conducting research and development activities with the objective to advance novel skeletal sarcomere targeted therapies for diseases and medical conditions associated with muscle weakness in non-neuromuscular indications.

    Comment?

  12. Cytokinetics Announces Presentations Relating to Tirasemtiv and...Read the original story

    Dec 5, 2014 | PR-inside.com

    South San Francisco, CA, December 5, 2014 - Cytokinetics, announced today that an oral presentation and four poster presentations relating to tirasemtiv were presented at the 25 International Symposium on ALS/MND held at the Square Brussels Meeting Centre in Brussels, Belgium. "We are pleased to present clinical and preclinical data relating to tirasemtiv, as well as other related analyses, at this important annual meeting of the ALS community," stated Fady I. Malik, M.D., Ph.D., Cytokinetics' Senior Vice President, Research and Development.

    Comment?

  13. Cytokinetics Announces Presentations Relating to Tirasemtiv at the...Read the original story

    Dec 1, 2014 | PR-inside.com

    South San Francisco, CA, December 1, 2014 - Cytokinetics, announced today that presentations relating to tirasemtiv are scheduled during the 25 International Symposium on ALS/MND to be held December 5-7, 2014 at the Square Brussels Meeting Centre in Brussels, Belgium. Tirasemtiv is the lead drug candidate from Cytokinetics' skeletal muscle contractility program.

    Comment?

  14. Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare ConferenceRead the original story

    Nov 26, 2014 | PR-inside.com

    South San Francisco, CA, November 26, 2014 - Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a panel presentation during the upcoming 26th Annual Piper Jaffray Healthcare Conference. The panel presentation is scheduled to occur on Wednesday, December 3, 2014 at 2:00 PM Eastern Time at the New York Palace Hotel in New York, New York.

    Comment?

  15. "Nodality, Inc. - Medical Equipment - Deals and Alliances Profile" PublishedRead the original story

    Nov 25, 2014 | PR-inside.com

    The company discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients. It develops molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the products targeting treatment management in hematological malignancies.

    Comment?

  16. Hyperion Therapeutics, Inc. (HPTX) - Financial and Strategic SWOT...Read the original story

    Nov 9, 2014 | PR-inside.com

    The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

    Comment?

  17. Recent Study: Catalyst Biosciences, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances ProfileRead the original story

    Nov 9, 2014 | PR-inside.com

    It undertakes the discovery and development of next generation biopharmaceuticals based on engineered human proteases platform technology. The company mainly focuses on the development of products for hemostasis and anti-complement.

    Comment?

  18. Cytokinetics Provides Development Program Update for Omecamtiv MecarbilRead the original story

    Oct 27, 2014 | PR-inside.com

    Over 275 Patients Enrolled in COSMIC-HF; Data Monitoring Committee Recommends Continuation with No Changes to the Protocol Phase I Pharmacokinetic and Safety Study Comparing Japanese and Caucasian Volunteers Completed SOUTH SAN FRANCISCO, CA, October 27, 2014 - Cytokinetics, Incorporated provided an update today relating to omecamtiv mecarbil, the company's lead drug candidate from its cardiac muscle contractility program. The company announced that COSMIC-HF has enrolled over 275 patients towards the objective of 450 patients in the ongoing expansion phase of the trial.

    Comment?

  19. Cytokinetics Provides Development Program Update for TirasemtivRead the original story

    Oct 20, 2014 | PR-inside.com

    Robust Effects of Tirasemtiv on Slow Vital Capacity Observed in BENEFIT-ALS Support Progression to Phase III Company Believes Effects on Slow Vital Capacity Could Support Registration Path For Tirasemtiv SOUTH SAN FRANCISCO, CA, October 20, 2014 - Cytokinetics, Incorporated provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful.

    Comment?

  20. Cytokinetics to Announce Third Quarter Results on October 30, 2014Read the original story

    Oct 16, 2014 | PR-inside.com

    South San Francisco, CA., October 16, 2014, - Cytokinetics, Incorporated announced today that it is scheduled to report third quarter results on Thursday, October 30, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

    Comment?

South San Francisco Job Listings
View or post South San Francisco job listings on Topix.
South San Francisco Real Estate
News, listings, and foreclosures in South San Francisco from Topix.
South San Francisco Mortgages
Find mortgage rates in South San Francisco on Topix.